Argent Biopharma Ltd
Company Profile
Business description
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.
Contact
295 Rokeby Road
Suite 1
SubiacoWA6008
AUST: +61 865552950
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Fears of deteriorating loan quality sends bank share plummeting
stocks
Why it’s not all bad news for Flight Centre following downgrade
stocks
Chart of the Week: What 650 IPOs reveal about long-term performance
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,964.20 | 1.20 | -0.01% |
| CAC 40 | 8,360.64 | 70.97 | -0.84% |
| DAX 40 | 24,641.85 | 352.98 | -1.41% |
| Dow JONES (US) | 51,905.04 | 15.58 | -0.03% |
| FTSE 100 | 10,484.19 | 45.70 | -0.43% |
| HKSE | 22,671.86 | 405.05 | -1.76% |
| NASDAQ | 25,260.52 | 98.08 | -0.39% |
| Nikkei 225 | 69,360.88 | 3,005.46 | -4.15% |
| NZX 50 Index | 13,495.24 | 2.19 | 0.02% |
| S&P 500 | 7,347.07 | 10.42 | -0.14% |
| S&P/ASX 200 | 8,764.20 | 0.20 | 0.00% |
| SSE Composite Index | 4,027.26 | 93.02 | -2.26% |